Memy I

a novel murine model for uterine leiomyoma using adenovirus-enhanced human fibroid explants in severe combined immune deficiency mice

Memy H. Hassan, Eduardo Eyzaguirre, Hossam M M Arafa, Farid M A Hamada, Salama A. Salama, Ayman Al-Hendy

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

Objective: This study was undertaken to develop a representative murine model for human leiomyoma. Study Design: Human fibroid tumor tissues were cut into small pieces and treated with medium alone, adenoviral-β-galactosidase, adenoviral-vascular endothelial growth factor-A, adenoviral-cyclooxygenase-2, or both adenoviral-vascular endothelial growth factor-A and adenoviral- cyclooxygenase-2. Tissue pieces were inserted subcutaneously in the flank of each severe combined immunodeficient mouse. The developed lesion was measured twice per week. Xenograft tissues were harvested after 30 days and analyzed. Results: Tissue pieces transfected with both adenoviral-cyclooxygenase-2 and adenoviral-vascular endothelial growth factor-A continued to grow up to 30 days postimplantation. The number of proliferating and apoptotic cells, as well as the expression of smooth muscle actin, desmin, vimentin, estrogen receptors, and progesterone receptors was similar between retrieved grafts from that group and the original patient tissue. Furthermore, hematoxylin and eosin and Masson's Trichrome stains confirmed this similarity. Conclusion: Human uterine leiomyoma xenografts, pretreated with both adenoviral- cyclooxygenase-2 and adenoviral-vascular endothelial growth factor-A and implanted subcutaneously in severe combined immunodeficient mice, represent a novel model for human uterine leiomyoma.

Original languageEnglish (US)
JournalAmerican Journal of Obstetrics and Gynecology
Volume199
Issue number2
DOIs
StatePublished - Aug 2008

Fingerprint

Human Adenoviruses
Severe Combined Immunodeficiency
Leiomyoma
Cyclooxygenase 2
Vascular Endothelial Growth Factor A
SCID Mice
Heterografts
Galactosidases
Desmin
Vimentin
Progesterone Receptors
Hematoxylin
Eosine Yellowish-(YS)
Estrogen Receptors
Smooth Muscle
Actins
Transplants

Keywords

  • cyclooxygenase-2
  • leiomyoma models
  • severe combined immunodeficient mice
  • uterine leiomyoma
  • vascular endothelial growth factor-A

ASJC Scopus subject areas

  • Medicine(all)
  • Obstetrics and Gynecology

Cite this

Memy I : a novel murine model for uterine leiomyoma using adenovirus-enhanced human fibroid explants in severe combined immune deficiency mice. / Hassan, Memy H.; Eyzaguirre, Eduardo; Arafa, Hossam M M; Hamada, Farid M A; Salama, Salama A.; Al-Hendy, Ayman.

In: American Journal of Obstetrics and Gynecology, Vol. 199, No. 2, 08.2008.

Research output: Contribution to journalArticle

@article{207d85241668487f82adc59b35f4df4a,
title = "Memy I: a novel murine model for uterine leiomyoma using adenovirus-enhanced human fibroid explants in severe combined immune deficiency mice",
abstract = "Objective: This study was undertaken to develop a representative murine model for human leiomyoma. Study Design: Human fibroid tumor tissues were cut into small pieces and treated with medium alone, adenoviral-β-galactosidase, adenoviral-vascular endothelial growth factor-A, adenoviral-cyclooxygenase-2, or both adenoviral-vascular endothelial growth factor-A and adenoviral- cyclooxygenase-2. Tissue pieces were inserted subcutaneously in the flank of each severe combined immunodeficient mouse. The developed lesion was measured twice per week. Xenograft tissues were harvested after 30 days and analyzed. Results: Tissue pieces transfected with both adenoviral-cyclooxygenase-2 and adenoviral-vascular endothelial growth factor-A continued to grow up to 30 days postimplantation. The number of proliferating and apoptotic cells, as well as the expression of smooth muscle actin, desmin, vimentin, estrogen receptors, and progesterone receptors was similar between retrieved grafts from that group and the original patient tissue. Furthermore, hematoxylin and eosin and Masson's Trichrome stains confirmed this similarity. Conclusion: Human uterine leiomyoma xenografts, pretreated with both adenoviral- cyclooxygenase-2 and adenoviral-vascular endothelial growth factor-A and implanted subcutaneously in severe combined immunodeficient mice, represent a novel model for human uterine leiomyoma.",
keywords = "cyclooxygenase-2, leiomyoma models, severe combined immunodeficient mice, uterine leiomyoma, vascular endothelial growth factor-A",
author = "Hassan, {Memy H.} and Eduardo Eyzaguirre and Arafa, {Hossam M M} and Hamada, {Farid M A} and Salama, {Salama A.} and Ayman Al-Hendy",
year = "2008",
month = "8",
doi = "10.1016/j.ajog.2008.02.010",
language = "English (US)",
volume = "199",
journal = "American Journal of Obstetrics and Gynecology",
issn = "0002-9378",
publisher = "Mosby Inc.",
number = "2",

}

TY - JOUR

T1 - Memy I

T2 - a novel murine model for uterine leiomyoma using adenovirus-enhanced human fibroid explants in severe combined immune deficiency mice

AU - Hassan, Memy H.

AU - Eyzaguirre, Eduardo

AU - Arafa, Hossam M M

AU - Hamada, Farid M A

AU - Salama, Salama A.

AU - Al-Hendy, Ayman

PY - 2008/8

Y1 - 2008/8

N2 - Objective: This study was undertaken to develop a representative murine model for human leiomyoma. Study Design: Human fibroid tumor tissues were cut into small pieces and treated with medium alone, adenoviral-β-galactosidase, adenoviral-vascular endothelial growth factor-A, adenoviral-cyclooxygenase-2, or both adenoviral-vascular endothelial growth factor-A and adenoviral- cyclooxygenase-2. Tissue pieces were inserted subcutaneously in the flank of each severe combined immunodeficient mouse. The developed lesion was measured twice per week. Xenograft tissues were harvested after 30 days and analyzed. Results: Tissue pieces transfected with both adenoviral-cyclooxygenase-2 and adenoviral-vascular endothelial growth factor-A continued to grow up to 30 days postimplantation. The number of proliferating and apoptotic cells, as well as the expression of smooth muscle actin, desmin, vimentin, estrogen receptors, and progesterone receptors was similar between retrieved grafts from that group and the original patient tissue. Furthermore, hematoxylin and eosin and Masson's Trichrome stains confirmed this similarity. Conclusion: Human uterine leiomyoma xenografts, pretreated with both adenoviral- cyclooxygenase-2 and adenoviral-vascular endothelial growth factor-A and implanted subcutaneously in severe combined immunodeficient mice, represent a novel model for human uterine leiomyoma.

AB - Objective: This study was undertaken to develop a representative murine model for human leiomyoma. Study Design: Human fibroid tumor tissues were cut into small pieces and treated with medium alone, adenoviral-β-galactosidase, adenoviral-vascular endothelial growth factor-A, adenoviral-cyclooxygenase-2, or both adenoviral-vascular endothelial growth factor-A and adenoviral- cyclooxygenase-2. Tissue pieces were inserted subcutaneously in the flank of each severe combined immunodeficient mouse. The developed lesion was measured twice per week. Xenograft tissues were harvested after 30 days and analyzed. Results: Tissue pieces transfected with both adenoviral-cyclooxygenase-2 and adenoviral-vascular endothelial growth factor-A continued to grow up to 30 days postimplantation. The number of proliferating and apoptotic cells, as well as the expression of smooth muscle actin, desmin, vimentin, estrogen receptors, and progesterone receptors was similar between retrieved grafts from that group and the original patient tissue. Furthermore, hematoxylin and eosin and Masson's Trichrome stains confirmed this similarity. Conclusion: Human uterine leiomyoma xenografts, pretreated with both adenoviral- cyclooxygenase-2 and adenoviral-vascular endothelial growth factor-A and implanted subcutaneously in severe combined immunodeficient mice, represent a novel model for human uterine leiomyoma.

KW - cyclooxygenase-2

KW - leiomyoma models

KW - severe combined immunodeficient mice

KW - uterine leiomyoma

KW - vascular endothelial growth factor-A

UR - http://www.scopus.com/inward/record.url?scp=47949123358&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=47949123358&partnerID=8YFLogxK

U2 - 10.1016/j.ajog.2008.02.010

DO - 10.1016/j.ajog.2008.02.010

M3 - Article

VL - 199

JO - American Journal of Obstetrics and Gynecology

JF - American Journal of Obstetrics and Gynecology

SN - 0002-9378

IS - 2

ER -